Search
                    Crohn's Disease Clinical Trials
A listing of 32  Crohn's Disease  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 32
        
                There are currently 32 active clinical trials seeking participants for Crohn's Disease research studies. The states with the highest number of trials for Crohn's Disease participants are Florida, Texas, California and New York.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period.             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 19 years
            Trial Updated:
                08/21/2025
            
            Locations: UCSF Medical Center at Mission Bay, San Francisco, California  +59 locations         
        
        
            Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
        
            
        
    
                
                                    A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
                                
            
            
        Recruiting
                            
            
                Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission).
Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), partici...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                08/20/2025
            
            Locations: East View Medical Research, Mobile, Alabama  +15 locations         
        
        
            Conditions: Ulcerative Colitis, Crohn's Disease
        
            
        
    
                
                                    Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
                                
            
            
        Recruiting
                            
            
                Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD....  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/18/2025
            
            Locations: Digestive Health Specialists /ID# 266216, Dothan, Alabama  +222 locations         
        
        
            Conditions: Crohn's Disease
        
            
        
    
                
                                    Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
                                
            
            
        Recruiting
                            
            
                The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal pro...  Read More             
        
        
    Gender:
                ALL
            Ages:
                2 years and above
            Trial Updated:
                08/18/2025
            
            Locations: Brain Inflammation Collaborative, Delafield, Wisconsin         
        
        
            Conditions: ME/CFS, Post-Acute COVID-19 Syndrome, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Bipolar Disorder (BPD), Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Major Depression, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
        
            
        
    
                
                                    Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/18/2025
            
            Locations: Center for Colitis and Crohns Disease University of California, San Francisco, California  +72 locations         
        
        
            Conditions: Crohn's Disease
        
            
        
    
                
                                    A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 17 years
            Trial Updated:
                08/14/2025
            
            Locations: Connecticut Children's Medical Center, Hartford, Connecticut  +68 locations         
        
        
            Conditions: Crohn's Disease
        
            
        
    
                
                                    A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
                                
            
            
        Recruiting
                            
            
                The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 16 years and 80 years
            Trial Updated:
                08/13/2025
            
            Locations: Digestive Health Specialists ( Site 5064), Dothan, Alabama  +421 locations         
        
        
            Conditions: Crohn's Disease
        
            
        
    
                
                                    Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
                                
            
            
        Recruiting
                            
            
                Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 2 years and 17 years
            Trial Updated:
                08/11/2025
            
            Locations: UCSF Benioff Children's Hospital - Oakland /ID# 262217, Oakland, California  +77 locations         
        
        
            Conditions: Crohn's Disease
        
            
        
    
                
                                    A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
                                
            
            
        Recruiting
                            
            
                This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/05/2025
            
            Locations: Gastro Care Institute - Site Number: 8400001, Lancaster, California  +8 locations         
        
        
            Conditions: Crohn's Disease
        
            
        
    
                
                                    A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
                                
            
            
        Recruiting
                            
            
                This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                08/04/2025
            
            Locations: Mirador Therapeutics Selected Site, Little Rock, Arkansas  +15 locations         
        
        
            Conditions: Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
        
            
        
    
                
                                    A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
                                
            
            
        Recruiting
                            
            
                This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD.
This study will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatm...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/04/2025
            
            Locations: GI Alliance - Sun City- Site Number : 8400020, Sun City, Arizona  +99 locations         
        
        
            Conditions: Crohn's Disease
        
            
        
    
                
                                    A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
                                
            
            
        Recruiting
                            
            
                This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 85 years
            Trial Updated:
                07/29/2025
            
            Locations: Gastro Care Institute, Lancaster, California  +141 locations         
        
        
            Conditions: Inflammatory Bowel Diseases, Crohn's Disease
        
            
        
    1 - 12 of 32
            